Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170366178> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3170366178 endingPage "S163" @default.
- W3170366178 startingPage "S163" @default.
- W3170366178 abstract "Fremanezumab is indicated for the prevention of migraine in adults in both chronic migraine (CM) and episodic migraine (EM). There remains some debate around where fremanezumab should be positioned in the treatment pathway for migraine, and so this study investigated the cost-effectiveness of fremanezumab following two inadequate treatment responses (failures) on other migraine preventive treatments. A semi-Markov cost-economic model that distributed patients across monthly migraine day (MMD) states (0-28 MMDs) was populated with efficacy and patient baseline data from the full patient population of the FOCUS clinical trial (NCT03308968). The following main assumptions were used: 10-year time horizon; non-responder patients (those with<30%[CM]/50%[EM] reduction in MMDs) stop treatment after 12-week trial; annual positive stopping for 20% of currently treated patients; healthcare resource use from National Health and Wellness Survey; costs from NHS reference costs and British National Formulary (2019 prices); utilities from FOCUS trial Migraine-Specific Quality Of Life; and discounting at 3.5%. Best supportive care (acute migraine treatment only, modelled using FOCUS placebo data) was the comparator in this analysis, as insufficient data were available to allow a network-meta analysis comparison to onabotulinumtoxinA. In CM, fremanezumab has an incremental cost-effectiveness ratio (ICER) value of £13,062/quality-adjusted life-year (QALY) and of £19,174/QALY versus BSC in EM. Sensitivity analyses showed the model was robust to changes in main inputs and was most sensitive to changes in fremanezumab drug acquisition cost, baseline monthly migraine days, analysis timeframe, and discontinuation rates. In probabilistic analyses (1,000 replications) fremanezumab was highly likely to be cost-effective at a willingness-to-pay threshold of £30,000/QALY. Fremanezumab has been found to be cost-effective after previous inadequate response to two or more previous migraine preventive treatments." @default.
- W3170366178 created "2021-06-22" @default.
- W3170366178 creator A5010624690 @default.
- W3170366178 creator A5031700821 @default.
- W3170366178 creator A5032799784 @default.
- W3170366178 creator A5048130857 @default.
- W3170366178 creator A5071238973 @default.
- W3170366178 date "2021-06-01" @default.
- W3170366178 modified "2023-09-30" @default.
- W3170366178 title "PND26 The Cost-Effectiveness of Fremanezumab in Patients with Migraine Who Have Failed Two or More Previous Migraine Preventive Therapies From a UK Healthcare System Perspective" @default.
- W3170366178 doi "https://doi.org/10.1016/j.jval.2021.04.810" @default.
- W3170366178 hasPublicationYear "2021" @default.
- W3170366178 type Work @default.
- W3170366178 sameAs 3170366178 @default.
- W3170366178 citedByCount "1" @default.
- W3170366178 countsByYear W31703661782021 @default.
- W3170366178 crossrefType "journal-article" @default.
- W3170366178 hasAuthorship W3170366178A5010624690 @default.
- W3170366178 hasAuthorship W3170366178A5031700821 @default.
- W3170366178 hasAuthorship W3170366178A5032799784 @default.
- W3170366178 hasAuthorship W3170366178A5048130857 @default.
- W3170366178 hasAuthorship W3170366178A5071238973 @default.
- W3170366178 hasBestOaLocation W31703661781 @default.
- W3170366178 hasConcept C100406419 @default.
- W3170366178 hasConcept C112930515 @default.
- W3170366178 hasConcept C126322002 @default.
- W3170366178 hasConcept C142724271 @default.
- W3170366178 hasConcept C1862650 @default.
- W3170366178 hasConcept C194828623 @default.
- W3170366178 hasConcept C204787440 @default.
- W3170366178 hasConcept C27081682 @default.
- W3170366178 hasConcept C2778541695 @default.
- W3170366178 hasConcept C2778715236 @default.
- W3170366178 hasConcept C2908647359 @default.
- W3170366178 hasConcept C2910587157 @default.
- W3170366178 hasConcept C3019080777 @default.
- W3170366178 hasConcept C512399662 @default.
- W3170366178 hasConcept C535046627 @default.
- W3170366178 hasConcept C71924100 @default.
- W3170366178 hasConcept C99454951 @default.
- W3170366178 hasConceptScore W3170366178C100406419 @default.
- W3170366178 hasConceptScore W3170366178C112930515 @default.
- W3170366178 hasConceptScore W3170366178C126322002 @default.
- W3170366178 hasConceptScore W3170366178C142724271 @default.
- W3170366178 hasConceptScore W3170366178C1862650 @default.
- W3170366178 hasConceptScore W3170366178C194828623 @default.
- W3170366178 hasConceptScore W3170366178C204787440 @default.
- W3170366178 hasConceptScore W3170366178C27081682 @default.
- W3170366178 hasConceptScore W3170366178C2778541695 @default.
- W3170366178 hasConceptScore W3170366178C2778715236 @default.
- W3170366178 hasConceptScore W3170366178C2908647359 @default.
- W3170366178 hasConceptScore W3170366178C2910587157 @default.
- W3170366178 hasConceptScore W3170366178C3019080777 @default.
- W3170366178 hasConceptScore W3170366178C512399662 @default.
- W3170366178 hasConceptScore W3170366178C535046627 @default.
- W3170366178 hasConceptScore W3170366178C71924100 @default.
- W3170366178 hasConceptScore W3170366178C99454951 @default.
- W3170366178 hasLocation W31703661781 @default.
- W3170366178 hasOpenAccess W3170366178 @default.
- W3170366178 hasPrimaryLocation W31703661781 @default.
- W3170366178 hasRelatedWork W2907279008 @default.
- W3170366178 hasRelatedWork W2909305492 @default.
- W3170366178 hasRelatedWork W2948901586 @default.
- W3170366178 hasRelatedWork W3015996685 @default.
- W3170366178 hasRelatedWork W3094653551 @default.
- W3170366178 hasRelatedWork W3200629206 @default.
- W3170366178 hasRelatedWork W4206427645 @default.
- W3170366178 hasRelatedWork W4206992385 @default.
- W3170366178 hasRelatedWork W4213312366 @default.
- W3170366178 hasRelatedWork W4234294751 @default.
- W3170366178 hasVolume "24" @default.
- W3170366178 isParatext "false" @default.
- W3170366178 isRetracted "false" @default.
- W3170366178 magId "3170366178" @default.
- W3170366178 workType "article" @default.